Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance-Reference-Cited by-同舟云学术

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Published:2023-05-03 Issue:7960 Volume:617 Page:377-385
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Park Joon Seok^ORCID,Gazzaniga Francesca S.,Wu Meng,Luthens Amalia K.^ORCID,Gillis Jacob,Zheng Wen,LaFleur Martin W.,Johnson Sarah B.^ORCID,Morad Golnaz^ORCID,Park Elizabeth M.,Zhou Yifan,Watowich Stephanie S.^ORCID,Wargo Jennifer A.^ORCID,Freeman Gordon J.^ORCID,Kasper Dennis L.^ORCID,Sharpe Arlene H.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-023-06026-3.pdf

Reference36 articles.

1. Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).

2. Routy, B. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

3. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 350, 1084–1089 (2015).

4. Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).

5. Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481–1489 (2020).

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered T cells for Colorectal Cancer;Immunotherapy;2024-09-04

2. Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity;Cells;2024-08-27

3. Cancer and the Microbiome of the Human Body;Nutrients;2024-08-21

4. Microbiota-induced plastic T cells enhance immune control of antigen-sharing tumors;2024-08-15

5. PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells;2024-08-06